Powered by IST's

Notice of Results
RNS
RNS Number : 5893P
Vectura Group plc
26 October 2012



Vectura Group plc



Date of announcement of Interim Results for six months ended 30 September 2012





Chippenham, UK - 26 October, 2012: Vectura Group plc (LSE: VEC), will be announcing its results for the six months ended 30 September, 2012 on Tuesday 20 November 2012. A webcast of the event will be available on the Company's website at www.vectura.com.

QVA149 marketing application filed in Japan
RNS
RNS Number : 5150Q
Vectura Group plc
07 November 2012



QVA149 marketing application filed in Japan for once-daily maintenance treatment of COPD





Chippenham, UK - 7 November 2012: Vectura Group plc ("Vectura"; LSE: VEC) confirms the information released today by Novartis Pharma K.K., announcing that it has submitted an application in Japan for the registration of QVA149, an investigational fixed dose combination of two long-acting inhaled bronchodilators (indacaterol maleate and glycopyrronium bromide) as a once-daily treatment for chronic obstructive pulmonary disease (COPD).



COPD is a chronic, progressive lung disease that is caused by the inhalation of harmful substances such as cigarette smoke over a long period. Its major symptoms include cough, sputum, and dyspnea on exertion. COPD not only greatly decreases the quality of life for patients, but is also a life-threatening disease because its symptoms progress and might eventually lead to respiratory failure.



The application for QVA149 was filed to the European Medicines Agency in October 2012 and the US application is planned for 2014.



Novartis also received approval for glycopyrronium bromide in Japan in September 2012 (SeebriÒInhalation Capsules, 50 mg), and was approved in the EU during the same month (under the trade name Seebri® Breezhaler®). The product has since been launched in Germany and the UK and approvals have also been granted in Canada and Australia.



Dr Chris Blackwell, Chief Executive of Vectura:

"QVA149 continues to make excellent progress with its potential to treat patients suffering from COPD. This disease is progressive and debilitating for sufferers."

sp steadily moving up,some good news due?

breaking out?

20 February 2013

Chippenham, UK 20 Feb 2013: Vectura Group plc ("Vectura"; LSE: VEC) announced today that that Dr Chris Blackwell, Vectura’s Chief Executive Officer, is scheduled to present at the Citi 2013 Global Healthcare Conference on Monday, 25th February 2013, at 15:00 PST. The conference will be held from February 25th – 26th, 2013 at the Hilton New York Hotel in New York City.

The presentation will be webcast live and can be reached on the following link

http://www.vectura.com/investors/reports/2013.aspx

Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software.

One of the Naked Traders tips for 2014

19 Dec Investec 170.00 Buy
19 Dec Canaccord... 150.00 Buy
19 Dec Finncap 180.00 Buy

cheers dc

8 Jan JP Morgan... N/A Overweight
6 Jan JP Morgan... 200.00 Overweight

Vectura Group PLC (VEC:LSE) set a new 52-week high during Friday's trading session when it reached 149.75. Over this period, the share price is up 62.40%.

Exciting times for this company.

200p I imagine in 2014.

Huge market in Germany.

Swedish approval of AirFluSal Forspiro

RNS


RNS Number : 6121X

Vectura Group plc

14 January 2014








Vectura Group plc



Swedish Regulatory Authority confirm approval of AirFluSal® Forspiro®





Chippenham, UK - 14 January 2014: Vectura Group plc (LSE: VEC; "Vectura" or "the Company") confirms that our partner, Sandoz, has today received Swedish marketing authorisation for AirFluSal® Forspiro® (formerly known as VR315), an innovative new inhaler for patients with asthma and chronic obstructive pulmonary disease (COPD).



The product was first approved in Denmark on December 18th, 2013 and Germany on January 13th, 2014. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.



Sweden has approved the 50-500µg and 50-250µg dosage forms for the continuous treatment of patients above 12 years of age with persistent asthma or for symptomatic treatment of COPD in the same patient group. The product's safety, efficacy and equivalence have been proven in multiple clinical trials1,2.



The receipt of the marketing authorisations in Sweden, Germany and Denmark follows the successful completion of EU decentralised procedures also including Norway for the 50-500 µg and 50-250 µg dosage forms and for the 50-500 µg dosage form Germany, Belgium, Bulgaria, Hungary, Luxembourg and Romania. We will communicate as and when further market approvals are received.



Vectura initially developed the VR315 product and created the design of the innovative inhaler, before licensing the asset to Sandoz in 2006. It was subsequently developed in collaboration with Vectura as AirFluSal® Forspiro® by Aeropharm GmbH in Rudolstadt, Germany, Sandoz' global respiratory Center of Excellence. The innovative and intuitive to use design of the inhaler was awarded the Red Dot Product Design award in 2011, an internationally recognized quality seal awarded by the Design Zentrum Nordrhein Westfalen in Essen, Germany.



[1] P Kuna, I Gath, U Thyroff-Friesinger, S Jones. Equivalence of an innovative multidose salmeterol/fluticasone dry powder inhaler vs

comparator in paediatric asthma. Submitted ERS - Reference September 2013

[2]Sandoz data on file

German approval of AirFluSal Forspiro

RNS


RNS Number : 5123X

Vectura Group plc

13 January 2014








Vectura Group plc



German Regulatory Authority confirm approval of AirFluSal® Forspiro®





Chippenham, UK - 13 January 2014: Vectura Group plc (LSE: VEC; "Vectura" or "the Company") confirms that our partner, Sandoz, has today received German marketing authorisation for AirFluSal® Forspiro® (formerly known as VR315), an innovative new inhaler for patients with asthma and chronic obstructive pulmonary disease (COPD). The receipt of the German marketing authorisation by Sandoz triggers a milestone payment to Vectura of €1.5 million.

The product was first approved in Denmark on December 18th, 2013. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.

Germany has approved the 50µg-500µg dosage form for the continuous treatment of patients above 12 years of age with persistent asthma or for symptomatic treatment of COPD in the same patient group. The product's safety, efficacy and equivalence have been proven in multiple clinical trials1,2.

"This approval further de-risks our high value respiratory generic portfolio in Europe and the Rest of the World and, provides a significant cash milestone to Vectura." said Chris Blackwell, CEO of Vectura. "Once launched, the royalty stream from AirFluSal® Forspiro® will contribute to Vectura's differentiated top line growth".

The receipt of the marketing authorisations in Germany and Denmark follows the successful completion of EU decentralised procedures which also include Belgium, Bulgaria, Hungary, Luxembourg, Romania, Sweden and Norway. We will communicate as and when further market approvals are received.



Vectura initially developed the VR315 product and created the design of the innovative inhaler, before licensing the asset to Sandoz in 2006. It was subsequently developed in collaboration with Vectura as AirFluSal® Forspiro® by Aeropharm GmbH in Rudolstadt, Germany, Sandoz' global respiratory Center of Excellence. The innovative and intuitive to use design of the inhaler was awarded the Red Dot Product Design award in 2011, an internationally recognized quality seal awarded by the Design Zentrum Nordrhein Westfalen in Essen, Germany.



[1] P Kuna, I Gath, U Thyroff-Friesinger, S Jones. Equivalence of an innovative multidose salmeterol/fluticasone dry powder inhaler vs

comparator in paediatric asthma. Submitted ERS - Reference September 2013

[2]Sandoz data on file

-Ends-

14 Jan N+1 Singer 110.00 Sell
14 Jan Finncap 180.00 Buy

Hungary approval of AirFluSal Forspiro

RNS


RNS Number : 8443X

Vectura Group plc

16 January 2014



Hungarian Regulatory Authority confirm approval of AirFluSal® Forspiro®





Chippenham, UK - 16 January 2014: Vectura Group plc (LSE: VEC; "Vectura" or "the Company") confirms that our partner, Sandoz, has received marketing authorisation in Hungary for AirFluSal® Forspiro® (formerly known as VR315), an innovative new inhaler for patients with asthma and chronic obstructive pulmonary disease (COPD).

The product was first approved in Denmark on December 18th, 2013, with subsequent marketing authorisations received earlier this week in Germany and Sweden. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.

Hungary has approved the 50-500µg dosage form for the continuous treatment of patients above 12 years of age with persistent asthma or for symptomatic treatment of COPD in adults. The product's safety, efficacy and equivalence have been proven in multiple clinical trials1,2.

Vectura initially developed the VR315 product and created the design of the innovative inhaler, before licensing the asset to Sandoz in 2006. It was subsequently developed in collaboration with Vecturaas AirFluSal® Forspiro® by Aeropharm GmbH in Rudolstadt, Germany, Sandoz' global respiratory Center of Excellence. The innovative and intuitive to use design of the inhaler was awarded the Red Dot Product Design award in 2011, an internationally recognized quality seal awarded by the Design Zentrum Nordrhein Westfalen in Essen, Germany.



[1]P Kuna, I Gath, U Thyroff-Friesinger, S Jones. Equivalence of an innovative multidose salmeterol/fluticasone dry powder inhaler vs

comparator in paediatric asthma. Submitted ERS - Reference September 2013

[2]Sandoz data on file

-Ends-

:-))

Romanian approval of AirFluSal Forspiro

RNS


RNS Number : 8026Y

Vectura Group plc

29 January 2014






Vectura Group plc



Romanian Regulatory Authority confirm approval of AirFluSal® Forspiro®





Chippenham, UK - 29 January 2014: Vectura Group plc (LSE: VEC; "Vectura" or "the Company") confirms that our partner, Sandoz, has received marketing authorisation in Romania for AirFluSal® Forspiro® (formerly known as VR315), an innovative new inhaler for patients with asthma and chronic obstructive pulmonary disease (COPD). The receipt of the Romanian marketing authorisation by Sandoz triggers a milestone payment to Vectura of €1.5 million.

The product was first approved (and now launched) in Denmark on December 18th, 2013 with subsequent market authorisations received earlier in January 2014 in Germany, Sweden and Hungary. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.

Romania has approved the 50µg-500µg dosage form for the continuous treatment of patients above 12 years of age with persistent asthma or for symptomatic treatment of COPD. The product's safety, efficacy and equivalence have been proven in multiple clinical trials1,2.

Vectura initially developed the VR315 product and created the design of the innovative inhaler, before licensing the asset to Sandoz in 2006. It was subsequently developed in collaboration with Vectura as AirFluSal® Forspiro® by Aeropharm GmbH in Rudolstadt, Germany, Sandoz' global respiratory Center of Excellence. The innovative and intuitive to use design of the inhaler was awarded the Red Dot Product Design award in 2011, an internationally recognized quality seal awarded by the Design Zentrum Nordrhein Westfalen in Essen, Germany.



[1] Kuna, I. Gath, U. Thyroff-Friesinger, S. Jones. Equivalence of fluticasone propionate/salmeterol delivered via new multi-dose dry powder inhaler and accuhaler™ in adolescent and adult asthma. Ajrccm conference.2013.187.1_MeetingAbstracts.A2611



[2]Sandoz data on file

-Ends-

Bulgarian approval of AirFluSal Forspiro

RNS


RNS Number : 2893Z

Vectura Group plc

04 February 2014






Vectura Group plc



Bulgarian Regulatory Authority confirm approval of AirFluSal® Forspiro®





Chippenham, UK - 4 February 2014: Vectura Group plc (LSE: VEC; "Vectura" or "the Company") confirms that our partner, Sandoz, has received Bulgarian marketing authorisation for AirFluSal® Forspiro® (formerly known as VR315), an innovative new inhaler for patients with asthma and chronic obstructive pulmonary disease (COPD).

The product was first approved (and now launched) in Denmark on December 18th, 2013 with subsequent market authorisations received in January 2014 in Germany, Sweden, Hungary and Romania. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.

Bulgaria has approved the 50µg-500µg dosage form for the continuous treatment of patients above 12 years of age with persistent asthma or for symptomatic treatment of COPD. The product's safety, efficacy and equivalence have been proven in multiple clinical trials1,2.

Vectura initially developed the VR315 product and created the design of the innovative inhaler, before licensing the asset to Sandoz in 2006. It was subsequently developed in collaboration with Vectura as AirFluSal® Forspiro® by Aeropharm GmbH in Rudolstadt, Germany, Sandoz' global respiratory Center of Excellence. The innovative and intuitive to use design of the inhaler was awarded the Red Dot Product Design award in 2011, an internationally recognized quality seal awarded by the Design Zentrum Nordrhein Westfalen in Essen, Germany.



[1] Kuna, I. Gath, U. Thyroff-Friesinger, S. Jones. Equivalence of fluticasone propionate/salmeterol delivered via new multi-dose dry powder inhaler and accuhaler™ in adolescent and adult asthma. Ajrccm conference.2013.187.1_MeetingAbstracts.A2611



[2]Sandoz data on file





-Ends-

Norwegian approval of AirFluSal Forspiro

RNS


RNS Number : 7281Z

Vectura Group plc

10 February 2014






Vectura Group plc



Norwegian Regulatory Authority confirm approval of AirFluSal® Forspiro®





Chippenham, UK - 10 February 2014: Vectura Group plc (LSE: VEC; "Vectura" or "the Company") confirms that our partner, Sandoz, has received Norwegian marketing authorisation for AirFluSal® Forspiro® (formerly known as VR315), an innovative new inhaler for patients with asthma and chronic obstructive pulmonary disease (COPD).

The product was first approved (and now launched) in Denmark on December 18th, 2013 with subsequent market authorisations received in 2014 in Germany, Sweden, Hungary, Romania and Bulgaria. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.

Norway has approved the 50µg-500µg and 50µg-250µg dosage forms for the continuous treatment of patients above 12 years of age with persistent asthma or for symptomatic treatment of COPD. The product's safety, efficacy and equivalence have been proven in multiple clinical trials1,2.

Vectura initially developed the VR315 product and created the design of the innovative inhaler, before licensing the asset to Sandoz in 2006. It was subsequently developed in collaboration with Vectura as AirFluSal® Forspiro® by Aeropharm GmbH in Rudolstadt, Germany, Sandoz' global respiratory Center of Excellence. The innovative and intuitive to use design of the inhaler was awarded the Red Dot Product Design award in 2011, an internationally recognized quality seal awarded by the Design Zentrum Nordrhein Westfalen in Essen, Germany.



[1] Kuna, I. Gath, U. Thyroff-Friesinger, S. Jones. Equivalence of fluticasone propionate/salmeterol delivered via new multi-dose dry powder inhaler and accuhaler™ in adolescent and adult asthma. Ajrccm conference.2013.187.1_MeetingAbstracts.A2611



[2]Sandoz data on file

-Ends-

Belgian approval of AirFluSal Forspiro

RNS


RNS Number : 9176Z

Vectura Group plc

12 February 2014






Vectura Group plc



Belgian Regulatory Authority confirm approval of AirFluSal® Forspiro®





Chippenham, UK - 12 February 2014: Vectura Group plc (LSE: VEC; "Vectura" or "the Company") confirms that our partner, Sandoz, has received Belgian marketing authorisation for AirFluSal® Forspiro® (formerly known as VR315), an innovative new inhaler for patients with asthma and chronic obstructive pulmonary disease (COPD). The receipt of the Belgian marketing authorisation by Sandoz triggers a milestone payment to Vectura of €1.5 million.

The product was first approved (and now launched) in Denmark on December 18th, 2013 with subsequent market authorisations received in 2014 in Germany, Sweden, Hungary, Romania, Bulgaria and Norway. The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device. The product has now been launched in Denmark and Germany.

Belgium has approved the 50µg-500µg dosage form for the continuous treatment of patients above 12 years of age with persistent asthma or for symptomatic treatment of COPD. The product's safety, efficacy and equivalence have been proven in multiple clinical trials1,2.

Vectura initially developed the VR315 product and created the design of the innovative inhaler, before licensing the asset to Sandoz in 2006. It was subsequently developed in collaboration with Vectura as AirFluSal® Forspiro® by Aeropharm GmbH in Rudolstadt, Germany, Sandoz' global respiratory Center of Excellence. The innovative and intuitive to use design of the inhaler was awarded the Red Dot Product Design award in 2011, an internationally recognized quality seal awarded by the Design Zentrum Nordrhein Westfalen in Essen, Germany.



[1] Kuna, I. Gath, U. Thyroff-Friesinger, S. Jones. Equivalence of fluticasone propionate/salmeterol delivered via new multi-dose dry powder inhaler and accuhaler™ in adolescent and adult asthma. Ajrccm conference.2013.187.1_MeetingAbstracts.A2611



[2]Sandoz data on file

-Ends-